Eukarÿs has developed C3P3 RNA polymerase: a patented bioengineered enzyme which demultiplies biomedicines upstream production yields in mammalian cells
- cost reduction
- ability to produce hard-to-express medicines
- universal: any antibody, recombinant protein, VLP...
- no investment in new equipments
- compatible with all existing technologies
- no impact on biologic quality: glycosylation, folding...
Full freedom to operate
World-class Awards: Prix Galien, Sanofi Golden Ticket
9 publications: Nucleic Acids Research, Nature scientific reports, Journal of Virology...
3 patent families
Company Details
- Employees
- 3
- Founded
- 2010
- Address
- 4, Rue Pierre Fontaine, Évry,ile-De-France 91000,france
- Industry
- Biotechnology
- Website
- eukarys.com
- Keywords
- mRNA, C3P3 technology, RNA polymerases, Capping enzymes, genetics, genomics, molecular biology, messenger RNA, Synthetic gene therapy, Gene therapy, Synthetic gene vaccination.
- HQ
- Évry, Ile-de-France
Eukarÿs Questions
Eukarÿs's website is eukarys.com
Eukarÿs's LinkedIn profile is https://fr.linkedin.com/company/eukarys-sas
Eukarÿs has
3 employees.
View email and phone details for 3
employees at Eukarÿs.
Eukarÿs's industry is
Biotechnology
Eukarÿs's top competitors are
Mendus Ab,
Cellforcure By Seqens,
Innovaprep Llc,
Oxbridge Clinical,
Flaminem,
Genethon,
Full Circles Therapeutics Inc.,
Thalya,
Ispiron Biotechnologies,
Evoworks Bio.
Eukarÿs's categories are Biotechnology
Eukarÿs's founding year is 2010
